These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 37370117)

  • 1. Targeting the oncogenic transcription factor FOXM1 to improve outcomes in all subtypes of breast cancer.
    Katzenellenbogen BS; Guillen VS; Katzenellenbogen JA
    Breast Cancer Res; 2023 Jun; 25(1):76. PubMed ID: 37370117
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effective combination treatments for breast cancer inhibition by FOXM1 inhibitors with other targeted cancer drugs.
    Guillen VS; Ziegler Y; Gopinath C; Kumar S; Dey P; Plotner BN; Dawson NZ; Kim SH; Katzenellenbogen JA; Katzenellenbogen BS
    Breast Cancer Res Treat; 2023 Apr; 198(3):607-621. PubMed ID: 36847915
    [TBL] [Abstract][Full Text] [Related]  

  • 3. FOXM1 regulates expression of eukaryotic elongation factor 2 kinase and promotes proliferation, invasion and tumorgenesis of human triple negative breast cancer cells.
    Hamurcu Z; Ashour A; Kahraman N; Ozpolat B
    Oncotarget; 2016 Mar; 7(13):16619-35. PubMed ID: 26918606
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FOXM1 transcriptionally regulates expression of integrin β1 in triple-negative breast cancer.
    Hamurcu Z; Kahraman N; Ashour A; Ozpolat B
    Breast Cancer Res Treat; 2017 Jun; 163(3):485-493. PubMed ID: 28361350
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serotonin 5-HT7 receptor is a biomarker poor prognostic factor and induces proliferation of triple-negative breast cancer cells through FOXM1.
    Cınar V; Hamurcu Z; Guler A; Nurdinov N; Ozpolat B
    Breast Cancer; 2022 Nov; 29(6):1106-1120. PubMed ID: 36006564
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The forkhead transcription factor FOXM1 promotes endocrine resistance and invasiveness in estrogen receptor-positive breast cancer by expansion of stem-like cancer cells.
    Bergamaschi A; Madak-Erdogan Z; Kim YJ; Choi YL; Lu H; Katzenellenbogen BS
    Breast Cancer Res; 2014 Sep; 16(5):436. PubMed ID: 25213081
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reversal of endocrine resistance in breast cancer: interrelationships among 14-3-3ζ, FOXM1, and a gene signature associated with mitosis.
    Bergamaschi A; Christensen BL; Katzenellenbogen BS
    Breast Cancer Res; 2011 Jun; 13(3):R70. PubMed ID: 21707964
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HMGA1 promotes breast cancer angiogenesis supporting the stability, nuclear localization and transcriptional activity of FOXM1.
    Zanin R; Pegoraro S; Ros G; Ciani Y; Piazza S; Bossi F; Bulla R; Zennaro C; Tonon F; Lazarevic D; Stupka E; Sgarra R; Manfioletti G
    J Exp Clin Cancer Res; 2019 Jul; 38(1):313. PubMed ID: 31311575
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FOXM1 plays a role in autophagy by transcriptionally regulating Beclin-1 and LC3 genes in human triple-negative breast cancer cells.
    Hamurcu Z; Delibaşı N; Nalbantoglu U; Sener EF; Nurdinov N; Tascı B; Taheri S; Özkul Y; Donmez-Altuntas H; Canatan H; Ozpolat B
    J Mol Med (Berl); 2019 Apr; 97(4):491-508. PubMed ID: 30729279
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of FOXM1 as a specific marker for triple‑negative breast cancer.
    Tan Y; Wang Q; Xie Y; Qiao X; Zhang S; Wang Y; Yang Y; Zhang B
    Int J Oncol; 2019 Jan; 54(1):87-97. PubMed ID: 30365046
    [TBL] [Abstract][Full Text] [Related]  

  • 11. YTHDC1-dependent m6A modification modulated FOXM1 promotes glycolysis and tumor progression through CENPA in triple-negative breast cancer.
    Shen X; Zhong J; Yu P; Liu F; Peng H; Chen N
    Cancer Sci; 2024 Jun; 115(6):1881-1895. PubMed ID: 38566554
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MicroRNA profiling identifies Forkhead box transcription factor M1 (FOXM1) regulated miR-186 and miR-200b alterations in triple negative breast cancer.
    Hamurcu Z; Sener EF; Taheri S; Nalbantoglu U; Kokcu ND; Tahtasakal R; Cınar V; Guler A; Ozkul Y; Dönmez-Altuntas H; Ozpolat B
    Cell Signal; 2021 Jul; 83():109979. PubMed ID: 33744419
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting forkhead box M1 transcription factor in breast cancer.
    O'Regan RM; Nahta R
    Biochem Pharmacol; 2018 Aug; 154():407-413. PubMed ID: 29859987
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dual Suppressive Effect of miR-34a on the FOXM1/eEF2-Kinase Axis Regulates Triple-Negative Breast Cancer Growth and Invasion.
    Bayraktar R; Ivan C; Bayraktar E; Kanlikilicer P; Kabil NN; Kahraman N; Mokhlis HA; Karakas D; Rodriguez-Aguayo C; Arslan A; Sheng J; Wong S; Lopez-Berestein G; Calin GA; Ozpolat B
    Clin Cancer Res; 2018 Sep; 24(17):4225-4241. PubMed ID: 29748184
    [No Abstract]   [Full Text] [Related]  

  • 15. Aurora kinase A stabilizes FOXM1 to enhance paclitaxel resistance in triple-negative breast cancer.
    Yang N; Wang C; Wang J; Wang Z; Huang D; Yan M; Kamran M; Liu Q; Xu B
    J Cell Mol Med; 2019 Sep; 23(9):6442-6453. PubMed ID: 31359594
    [TBL] [Abstract][Full Text] [Related]  

  • 16. FOXM1 cistrome predicts breast cancer metastatic outcome better than FOXM1 expression levels or tumor proliferation index.
    Yau C; Meyer L; Benz S; Vaske C; Scott G; Egan B; Labhart P; Pourmand N; Benz CC
    Breast Cancer Res Treat; 2015 Nov; 154(1):23-32. PubMed ID: 26456572
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FoxM1 is a downstream target and marker of HER2 overexpression in breast cancer.
    Francis RE; Myatt SS; Krol J; Hartman J; Peck B; McGovern UB; Wang J; Guest SK; Filipovic A; Gojis O; Palmieri C; Peston D; Shousha S; Yu Q; Sicinski P; Coombes RC; Lam EW
    Int J Oncol; 2009 Jul; 35(1):57-68. PubMed ID: 19513552
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Resistance to FOXM1 inhibitors in breast cancer is accompanied by impeding ferroptosis and apoptotic cell death.
    Kumar S; Ziegler Y; Plotner BN; Flatt KM; Kim SH; Katzenellenbogen JA; Katzenellenbogen BS
    Breast Cancer Res Treat; 2024 Nov; 208(2):307-320. PubMed ID: 38980505
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Thiostrepton selectively targets breast cancer cells through inhibition of forkhead box M1 expression.
    Kwok JM; Myatt SS; Marson CM; Coombes RC; Constantinidou D; Lam EW
    Mol Cancer Ther; 2008 Jul; 7(7):2022-32. PubMed ID: 18645012
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FoxM1 promotes breast tumorigenesis by activating PDGF-A and forming a positive feedback loop with the PDGF/AKT signaling pathway.
    Yu G; Zhou A; Xue J; Huang C; Zhang X; Kang SH; Chiu WT; Tan C; Xie K; Wang J; Huang S
    Oncotarget; 2015 May; 6(13):11281-94. PubMed ID: 25869208
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.